DexCom, Inc. vs Exxon Mobil Corporation — how do they compare? DexCom, Inc. trades at $90.15 (market cap $33.79B), while Exxon Mobil Corporation trades at $159.21 (market cap $657.08B). The key difference: Exxon Mobil Corporation is far larger — about 19.4× DexCom, Inc.'s market cap, and Exxon Mobil Corporation pays a 2.58% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | XOM | |
|---|---|---|
Market Cap | $33.79B | $657.08B |
Sector | Health | Energy |
52-Week High | $89.53 | $171.52 |
52-Week Low | $54.84 | $106.13 |
Enterprise Value | $33.24B | $688.86B |
Dividend Yield | — | 2.58% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
ExxonMobil (XOM) trades at $159.79, up 4.48% today, showing strong momentum near its consensus price target of $163.71. The stock maintains a bullish technical outlook with support at $156 and resistance at $162. Recent earnings show mixed results with Q2 2026 missing expectations, but profitability remains solid with a 9.07% net margin and 12.55% ROE. The company benefits from high oil prices and strategic Permian Basin operations, though revenue has declined from $398.7B in 2022 to $323.9B in 2025.
XOM presents a balanced investment case with analyst consensus leaning toward Hold (51.85%). Upside potential exists from oil price strength and operational efficiency, but risks include volatile energy markets and declining revenue trends. The stock's current valuation at 20.57x P/E appears reasonable given stable dividends and strong cash flow generation. Institutional sentiment remains cautiously optimistic with price targets suggesting modest upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →